5169

Basic information

Product Description:

The EarlyTect Colon Cancer Test is a groundbreaking product that has been approved by the Korea Ministry of Food and Drug Safety. This approval was granted after rigorous clinical trials conducted at prestigious medical institutions such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center. These trials involved 585 men and women between the ages of 30 and 80 who were eligible subjects for the study.

The clinical trials for this test utilized fecal DNA samples and yielded impressive results. It was found that colorectal cancer (CRC) can be accurately diagnosed with a remarkable sensitivity and specificity of 90%. The EarlyTect Colon Cancer Test utilizes a qualitative real-time PCR approach to measure methylated Syndecan-2, a biomarker clinically associated with precancerous lesions of CRC, in stool DNA. This innovative testing method has opened new possibilities for the early detection and diagnosis of colorectal cancer.

It is crucial to note that the EarlyTect Colon Cancer Test is not meant to confirm the presence of colorectal cancer itself. Instead, if a subject receives a positive result from the test, it indicates the possibility of the existence of CRC or precancerous lesions of CRC. Subsequent diagnostic procedures and medical consultations will be necessary for confirming the presence of colorectal cancer.

Product Standard:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals seeking colorectal cancer screening
- Biomarker: SDC2 methylation

Please note that the price and transaction conditions for the EarlyTect Colon Cancer Test are negotiable. For detailed information, kindly request a quote that suits your needs.